SYS-CON MEDIA Authors: Jayaram Krishnaswamy, Lori MacVittie, Gilad Parann-Nissany, Unitiv Blog, Bob Gourley

News Feed Item

2014 Report on Select Cardiovascular Drugs in the GCC Region

DUBLIN, Ireland, January 27, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/7dmdjw/market_for_select) has announced the addition of the "2014 Report on Select Cardiovascular Drugs in the GCC Region" report to their offering. 


     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The local governments are increasingly focusing on improving the health and living standards of the population. Contraints in local manufacturing capacity and thriving counterfeit drugs market pose a major challenge but improved regulatory mechanism, increase in private sector participation coupled with rising private and public sector outlay and spend on healthcare presents a promising future for the industry.

This report focuses on the market for select cardiovascular drugs in the GCC region. Various market drivers in terms of changing lifestyle and rising disease incidence among the population has led to higher consumption of cardiovascular drugs in the region. Sensing the latent market opportunity, global pharma majors such as Novartis, Abbott, AstraZeneca have set up operations in the GCC region through local joint venture and distribution.

In addition to market forecast upto 2016, the report also provides interesting insights into key molecules used, top brands, drug prices, procurement process among government and retail institutions. The report will serve as a effective guide for the drug companies, distributors, hospitals and other stakeholders who wish to enter the GCC healthcare market. The report also has profiles of companies and distributors in the GCC region." 


Key Topics Covered: 

1. Methodology

2. Report Coverage
2.1 Geography
2.2 Therapeutic groups & drug molecules

3. Glossary of terms

4. Executive summary

5. Healthcare sector in GCC
5.1 Overview of the healthcare sector
5.2 Healthcare infrastructure

6. Pharmaceutical market in GCC
6.1 Overview of the pharmaceutical market
6.2 Domestic manufacturing
6.3 Foreign trade
6.4 Counterfeit drugs
6.5 Regulatory environment and registration procedure
6.6 Drug sourcing and pricing regulation
6.7 Share of purchase by Government vs. Private

7. Cardiovascular market for select drugs in GCC
7.1 Key health indicators
7.2 Disease incidence levels
7.3 Share of cardiovascular drugs by: hypertension, coronary artery disease & hyperlipidemia
7.4 Market size of cardiovascular drugs in GCC
7.5 Prices of Cardiovascular drugs in GCC
7.6 Top brands/suppliers of cardiovascular drugs in GCC

8. Profiles of key domestic pharmaceutical manufacturers
8.1 Tabuk Pharmaceuticals Manufacturing Company
8.2 Jamjoom Pharma
8.3 Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
8.4 Julphar - Gulf Pharmaceutical Industries
8.5 Global Pharma
8.6 Neo Pharma
8.7 Kuwait Saudi Pharmaceutical Industries (KSPICO)
8.8 National Pharmaceutical Industries Co. (NPI)
8.9 Oman Pharmaceutical Products Co. L.L.C 
8.10 Profiles of key pharmaceutical distributors in GCC

9. Annexure - Drugs price details by country - 2012


Companies Mentioned:

  • AstraZeneca
  • Global Pharma
  • Jamjoom Pharma
  • Julphar - Gulf Pharmaceutical Industries
  • Kuwait Saudi Pharmaceutical Industries
  • Merck & Co., Inc
  • National Pharmaceutical Industries Co
  • Neo Pharma
  • Novartis International AG
  • Oman Pharmaceutical Products Co. L.L.C
  • Pfizer, Inc
  • Sanofi S.A.
  • Saudi Pharmaceutical Industries & Medical Appliances Corporation
  • Tabuk Pharmaceuticals Manufacturing Company


For more information visit http://www.researchandmarkets.com/research/7dmdjw/market_for_select


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.